
Aurobindo Pharma shares in focus after European Commission nod for cancer drug Dazublys
Aurobindo Pharma shares will be in focus on Thursday after its wholly-owned step-down subsidiary, CuraTeQ Biologics, received marketing authorisation from the European Commission for its trastuzumab biosimilar, Dazublys. The approval follows a positive …